Stockscreener 앱 받기
4.27
3.17%
-0.14
시간 외 거래:
4.21
-0.06
-1.41%
전일 마감가:
$4.41
열려 있는:
$4.2
하루 거래량:
63,448
Relative Volume:
1.05
시가총액:
$54.87M
수익:
-
순이익/손실:
$-11.73M
주가수익비율:
-3.0884
EPS:
-1.3826
순현금흐름:
$-10.37M
1주 성능:
+4.40%
1개월 성능:
+17.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.20
$4.79
1주일 범위
$4.00
$4.79
52주 변동 폭
$1.80
$4.99
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
MDCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
4.27 | 54.87M | 0 | -11.73M | -10.37M | -1.3826 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive Investors
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma to acquire Antev in strategic biotech deal By Investing.com - Investing.com South Africa
Medicus Pharma to acquire Antev in strategic biotech deal - Investing.com Australia
Small cap wrap: Medicus Pharma, Arizona Gold & Silver, Plug Power... - Proactive Investors
Market movers: Nvidia, Plug Power, Medicus Pharma... - Proactive financial news
Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange Transaction - marketscreener.com
Medicus Pharma to Acquire Antev Ltd. in $75 Million Deal - TipRanks
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction - Malay Mail
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment - Proactive financial news
Medicus Pharma Ltd’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating - TipRanks
Medicus Pharma (NASDAQ:MDCX) Given Buy Rating at D. Boral Capital - Defense World
Medicus Pharma expands patient enrollment for skin cancer study By Investing.com - Investing.com Canada
Small cap wrap: Medicus Pharma, HIVE Digital Technologies, Spanish Mountain Gold... - Proactive Investors
Medicus Pharma expands basal cell carcinoma study after encouraging early data - Proactive financial news
Medicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma Treatment - TipRanks
Medicus Pharma expands patient enrollment for skin cancer study - Investing.com
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) - Newsfile
Medicus Pharma (CVE:MDC) Raised to Strong-Buy at D Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Raised to Strong-Buy at D Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Medicus Pharma initiated with a Buy at D. Boral Capital - TipRanks
Medicus Pharma Ltd. - FinancialContent
This Millrose Properties Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
FY2025 EPS Estimate for Medicus Pharma Lifted by Analyst - Defense World
Brokers Set Expectations for Medicus Pharma Q1 Earnings - The AM Reporter
Research Analysts Issue Forecasts for Medicus Pharma Q1 Earnings - Defense World
Research Analysts Set Expectations for Medicus Pharma Q1 Earnings - Defense World
Medicus Pharma secures $15 million funding option - MSN
Will Medicus' D-MNA Prove To Be A Non-Invasive, Effective Alternative To Mohs Surgery For BCC? - RTTNews
Medicus Pharma Ltd. SEC 10-K Report - TradingView
Medicus Pharma Ltd. (MDCX) reports earnings - Quartz
Healthcare Disruptors: AI, Telehealth and Cost Savings - Value The Markets
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out - WRAL.com
ValueTheMarkets Insights: Healthcare Climbs as Tech Stumbles in 2025 Shift - WRAL.com
While Big Pharma Stalls, One Small-Cap Breaks Out - TipRanks
Healthcare Climbs as Tech Stumbles in 2025 Shift - Value the Markets
Medicus Pharma cancels shareholder meeting notice By Investing.com - Investing.com Australia
Medicus Pharma cancels shareholder meeting notice - Investing.com
Pinpointing Hidden Stock Winners in a Volatile Market - Value The Markets
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%! - Value The Markets
Medicus Pharma announces annual meeting date - Investing.com
Medicus Pharma announces annual meeting date By Investing.com - Investing.com Australia
Advancing Oncology: Innovations in Treatment and Detection - Value The Markets
See Why Some Investors Are Watching This Biotech Company - Value The Markets
Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity - Value The Markets
The Biotech Stocks Tackling the World’s Most Common Cancer - Value The Markets
Medicus Pharma - The Pharma Letter
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):